Abstract
A 53-year-old woman had shown repeated, partial responses to chemotherapy for large, multiple liver metastases of sigmoid colon cancer. After a partial response to 5-fluorouracil plus leucovorin therapy, an 89.7% reduction of the 5-fluorouracil-resistant metastatic tumor was achieved by giving CPT-11 (irinotecan) at a dose of 100 mg/body per week. We suggest that CPT-11 should be recommended as an effective second-line treatment for unresectable liver metastases of colon cancer, after 5-fluorouracil-based chemotherapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469–475.
Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967–1972.
Laufman LR, Bukowski RM, Collier MA, Sullivan BA, McKinnis RA, Clendennin NJ, Guaspari A, Brenckman WD Jr. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993;11:1888–1893.
Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996;23:34–41.
Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995;31A:1283–1287.
Rothenberg ML, Kuhn JG, Burris III HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194–2204.
Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, the CPT-11 Gastrointestinal Cancer Study Group. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993;11:909–913.
Bugat R, Suc E, Rou gier Ph, Becouarn Y, Naieff I, Ychou M, Culine S, Extra JM, Adenis A, Ganem G, Giovannini M, Merrouche M, Ferrero F, Conroy T, Despax R, Mousseau I, Bekrada M, Mathieu-Boué A, Mahjoubi M, Herait P. CPT-11 (irinotecan) as second line therapy in advanced colorectal cancer: preliminary results of a multicentric phase II study. Dallas, Texas: 30th Annual Meeting of the American Society of Clinical Oncology; 14–17 May 1994 (abstr 586).
Rothenberg ML, Eckardt JR, Kuhn JG, Burris III HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128–1135.
Conti JA, Kemeny N, Saltz L, Tong W, Chou TC, Pulliam M. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer. Dallas, Texas: 30th Annual Meeting of the American Society of Clinical Oncology; 14–17 May 1994 (abstr 565).
Pitot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Dallas, Texas: 30th Annual Meeting of the American Society of Clinical Oncology; 14–17 May 1994 (abstr 573).
Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995;55:2116–2121.
Armand JP. CPT-11: clinical experience in phase I studies. Semin Oncol 1996;23:27–33.
Author information
Authors and Affiliations
About this article
Cite this article
Nomura, H., Takahashi, Y. & Mai, M. Irinotecan as second-line treatment for unresectable liver metastases of colon cancer. Int J Clin Oncol 3, 117–120 (1998). https://doi.org/10.1007/BF02492859
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02492859